Graeme Smith
Chief Scientific Officer Artios Pharma
Seminars
• Bringing together academic founders and investors to explore what makes DDR programs fundable
• Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures
• Offering insights into risk assessment, strategic partnerships, and scaling innovation
• Sharing preclinical and translational data on ATR inhibition in ATM-deficient cancers
• Presenting clinical results from Phase I showing strong efficacy, including a 50% objective response rate
• Highlighting the differentiated strategy of combining ATR inhibition with low-dose chemotherapy to overcome past limitations of monotherapy
• Showcasing patient vignettes and narratives to illustrate real-world impact and translational success
